REXAHN PHARMACEUTICALS, INC. 4
4 · REXAHN PHARMACEUTICALS, INC. · Filed Jan 27, 2015
Insider Transaction Report
Form 4
Suzdak Peter David
Chief Executive Officer
Transactions
- Award
Stock Option (right to purchase)
2015-01-23+1,100,000→ 1,100,000 totalExercise: $0.71Exp: 2025-01-23→ Common Stock (1,100,000 underlying)
Footnotes (1)
- [F1]Options will vest and be exercisable based on the following schedule: 275,000 on January 23, 2016, 275,000 on January 23, 2017, 275,000 on January 23, 2018, and 275,000 on January 23, 2019.